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RESEARCH ARTICLE
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Abstract
3D printing has the potential to deliver personalized implants and devices for obstetric and
gynecologic applications. The aim of this study is to engineer customizable and biodegrad-
able 3D printed implant materials that can elute estrogen and/or progesterone. All 3D con-
structs were printed using polycaprolactone (PCL) biodegradable polymer laden with
estrogen or progesterone and were subjected to hormone-release profile studies using
ELISA kits. Material thermal properties were tested using thermogravimetric analysis and
differential scanning calorimetry. The 3D printed constructs showed extended hormonal
release over a one week period. Cytocompatibility and bioactivity were assessed using a
luciferase assay. The hormone-laden 3D printed constructs demonstrated an increase in
luciferase activity and without any deleterious effects. Thermal properties of the PCL and
hormones showed degradation temperatures above that of the temperature used in the
additive manufacturing process–suggesting that 3D printing can be achieved below the deg-
radation temperatures of the hormones. Sample constructs in the shape of surgical meshes,
subdermal rods, intrauterine devices and pessaries were designed and printed. 3D printing
of estrogen and progesterone-eluting constructs was feasible in this proof of concept study.
These custom designs have the potential to act as a form of personalized medicine for drug
delivery and optimized fit based on patient-specific anatomy.
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Introduction
Major advances in biomedical engineering have led to new patient-specific technologies which
treat diseases using biocompatible materials as controlled drug delivery systems. Additive
manufacturing techniques, including Fused Deposition Modeling (FDM) 3D printing, boast
high speed, accuracy, affordability, and feasibility leading to its increased use in medicine and
biotechnology. Because of its rapid production and customizability, 3D printing has been used
to construct prostheses, human tissues, medical devices, and surgical implants for dental and
orthopedic applications [1–5].
Estrogens are available in various formulations and are administered via different routes
such as intramuscular, subcutaneous, intravenous, transdermal, vaginal, and oral. Estrogen,
progesterone, or combination formulations are variously used for contraception, regulation of
the menstrual cycle, hormone replacement therapy (HRT), and vaginal atrophy among others.
These drugs are delivered in a variety of forms. For example, extended steady-state release sub-
cutaneous HRT implants are usually in the shape of a small pellet, made by fusing pure crystals
of hormones, and are available at doses of 50–100 mg. Intrauterine devices (IUDs) are consid-
ered excellent long-term birth control because of their safety, efficacy, and ease of use [6].
These are small T-shaped devices, made of flexible plastic, are placed directly into the uterus,
releasing small amounts of a progestin for up to 12 years [7]. Pessaries are medical devices
used to treat pelvic organ prolapses by providing structural support to the uterus, vagina, blad-
der, and rectum [8], and are typically used in conjunction with local estrogen therapy. These
devices are made in different sizes and designs that are subject to patient needs, anatomy, and
physician preference [9].
Currently available obstetric and gynecologic implants are bulk manufactured with fixed
doses, whereas every individual is unique, requiring different doses of hormones. Differences
in IUD shapes and dosage concentrations leads to ectopic pregnancies, pelvic inflammatory
disease, uterine perforations [10–11]. Commercially available IUDs cannot account for the dif-
ferences between individuals. Bioactive 3D printing of IUDs and pessaries has the potential to
provide patient-specific devices while delivering extended release hormones. The purpose of
this study is to engineer customizable and biodegradable 3D printed implant material that can
elute estrogen or progesterone.
Materials and methods
Materials
The Polycaprolactone (PCL) pellets used for filament extrusion were purchased from Sigma-
Aldrich (St. Louis, MO). Hormones Estrone (E1) (SLE 1048), Estradiol (E2) (CAS 57-63-6)
and Estriol (E3) (CAS 50-27-1), and Progesterone (P) (CAS 57-83-0) were purchased from
PCCA, Houston, TX. Cell culture plates and other lab plastics were purchased from MidSci,
St. Louis, MO. Rosewell Park Memorial Institute Medium (RPMI), Dulbecco’s Modified
Eagle’s Medium (DMEM), fetal bovine serum (FBS), and penicillin-streptomycin-amphoteri-
cin (PSA) antibiotics were obtained from Life Technologies, Carlsbad, CA. Estrogen receptor
luciferase reporter T47D stable cell line (Sl-0002-NP) was purchased from Signosis, Inc. (Santa
Clara, CA). KJLC 705 silicone oil used for coating the beads before extrusion was purchased
from Kurt J. Lesker Company (Jefferson Hills, PA). The 3D printing equipment consists of an
ExtrusionBot extruder (ExtrusionBot, LLC Phoenix, AZ) and a MakerBot Replicator 5th Gen-
eration Desktop 3D printer (Makerbot Industries Brooklyn, NY). The nanodrop spectropho-
tometer was from Thermo Scientific (Wilmington, DE). Solidworks 2015 student edition 3D
computer aided design (CAD) program Dassault Systèmes (Waltham, MA) and Blender
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(Blender Foundation, Amsterdam, NL) were used for modeling. ELISA kits for E2 and E3 were
purchased from Enzo Life Sciences (Farmingdale, NY). To analyze ELISA assays, a SpectraMax
M2e Multimode microplate reader purchased from Molecular Devices (Sunnyvale, CA) was used.
The SEM was a Hitachi S-4800 (Schaumburg, IL). Liquid chromatography- tandem mass spec-
trometry (LC-MS/MS) was performed on an AB Sciex 3200 OTrap mass spectrometer (Foster
City, CA) interfaced with a Shimadzu UFLC HPLC system (Columbia, MD) using electrospray
ionization (ESI) in positive mode, and run using Analyst1 v.1.4.2 software. All chromatographic
separations were performed on a Nucleodur 100–5 C8 125 x 3 mm column (Macherey–Nagel,
Bethlehem, PA). Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC)
were performed on a TA Q5000 IR and TA DSC 2500 (New Castle, DE) respectively. X-ray dif-
fraction (XRD) was analyzed using Rigaku DMaxB instrument (Tokyo, JP).
Fabricating hormone loaded scaffolds
PCL thermoplastic pellets were used for loading hormones due to its low melting tempera-
tures, excellent biodegradability and biocompatibility. These pellets were coated with the
calculated amount (1% w/w) of hormones and extruded as filaments of 1.75 mm diameter,
which were used in Makerbot 1st generation desktop 3D printer to print customized im-
plant materials.
Coating pellets with hormones. To enable an even dispersion of hormones on the surface
of the commercially available PCL pellets, an oil coating method was used. To surface coat pel-
lets, KJL 705 silicone oil was chosen because of its thermal stability at elevated temperatures.
15 μl of silicone oil was added to a 20 gm batch of pellets which were then vortexed to evenly
and completely coat the pellets. Once vortexed, the pellets were transferred to another con-
tainer to avoid loss of drug powder due to sticking to the surface of the oil coated mixing con-
tainer. After switching containers, the calculated amount of hormones in powdered form was
added and the mixture was vortexed again. This process is illustrated in Fig 1.
Extruding hormone loaded filaments. An ExtrusionBot filament extruder was used to
extrude coated pellets. Since the 3D printer used requires a 1.75 mm diameter filament to
print, a metal die of the same diameter was used to extrude the filament. Each 20 gm batches
of E1, E2, E3, and progesterone were extruded at 90–100˚C.
Optimizing 3D printing parameters. 3D printer based on FDM is a very delicately bal-
anced machine. If filament-extrusion temperature, the speed of extrusion and speed of the
printer-head are not coordinated, the printing process does not yield constructs of the required
shape. An optimized process also involves complex integration between hardware, software and
material properties. Primary trials revealed that the printer-head temperature and filament feed
rate have a direct influence on the material flow for the fabrication of the scaffolds. For this rea-
son, optimization of printing parameters for PCL was focused mostly on printer-head tempera-
ture and filament feed rate. The minimum temperature of the printer-head that could print
PCL was determined, and the filament extruding rate was adjusted accordingly.
On the MakerBot 1st generation 3D printer, PCL prints at a lowest temperature of 100˚C,
and to compensate for this, the printer-head speed was reduced from a default 40 mm/s to 10
mm/s and increase the filament feed rate from a default 18 mm/s to 23 mm/s. All E1, E2, E3
and progesterone constructs were printed at 110˚C at a printer-head speed of 10 mm/s and a
constant filament-feed rate of 23 mm/s.
Scaffolds design and fabrication
All 3D models including IUDs, meshes, and pessaries were designed using Solidworks 2015
CAD software. Discs of 5 x 1 mm dimensions were printed for drug elution testing and in vitro
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cell cultures. IUDs and pessaries of different dimensions and shapes were also designed and
printed using the extruded filaments.
Scaffold characterization
The 3D printed hormonal scaffolds were subjected to physical and bioactive testing. Surface
morphology of the constructs was studied using SEM. Thermal properties were evaluated
Fig 1. The process of coating PCL pellets with hormones. A) Coating oil is added, B) Tube is vortexed, C) Pellets are transferred to a new tube, D)
Hormones are added, E) Tube is vortexed, F) Coated pellets are removed.
https://doi.org/10.1371/journal.pone.0182929.g001
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using TGA and DSC. Crystalline and amorphous states of the constructs were analyzed using
XRD. ELISA kits were used to study hormonal release from scaffolds, and Luciferase assay was
conducted to test the bioactivity of the hormonal discs.
Morphology. Extruded filaments and printed discs of different hormones were subjected
to SEM using S4800 Field Emission SEM, HITACHI (Schaumburg, IL) at different magnifica-
tions. Construct surface were coated with a thin film of gold before imaging to make them
conductive.
Thermal properties. Given that polymers undergo heating during 3D printing, thermal
degradation behavior of polymer, hormones and the 3D printed constructs were studied using
TA Instrument Q5000 IR. The samples were tested using ramp method. Samples were heated
from ambient temperature to 500˚C at a rate of 20˚C/min and changes in sample weight were
measured. Changes in melting temperatures (Tm) and glass transition temperatures (Tg) of
polymers due to addition of hormones were tested using DSC. Samples were heated from
-80˚C to 130˚C at a rate of 10˚C/min. Energy input (heat flow) was measured as a function of
temperature in this analysis. Both analyses were carried out in a nitrogen environment.
X-ray diffraction. Crystalline and amorphous properties were analyzed using XRD.
Rigaku DMaxB instrument was operated at 35K and 30mA to produce radiation from Copper.
Diffractions were measured within the range of scattering angles (2θ) of 10˚ to 50˚ with dwell
time of 2 min.
Absolute quantification of hormones using tandem MS/MS analysis. An LC-MS/MS
method was developed for the separation and quantification of different hormones in the scaf-
folds using mass spectrometry. A gradient elution method was employed with solvent A
(HPLC water and 0.1% formic acid) and solvent C (acetonitrile and 0.09% formic acid) as the
mobile phase solvents with a total run time of 14 min and flow rate of 0.3 mL/min. The elution
profile starts with 10% solvent C ramped to 60% in 8 min and 100% in next 2 min, followed by
post-equilibration with solvent C to 10% for 4 min. The UV detector was set at 280 nm. A mul-
tiple reaction monitoring method was developed with 1mM standard solutions of E1, E2, E3
using the signature transitions for each analyte- E1, E3 (271.3/133.0) and E2 (255.0/159.0).
Method development included validation for accuracy, specificity, sensitivity, determination
of response linearity, limit of detection (LOD), lower limit of quantification (LLOQ) and possi-
ble matrix effects and carryover.
Samples were prepared by suspension and extraction of the discs in diethyl ether. The dried
extract is resuspended in 50 uL of solvent A and analyzed by LC-MS.
Hormone elution profile. To calculate the amount of hormone eluting from the con-
structs, an elution study was conducted. Saline was used for sample collection. Samples from
E2 and E3 were collected at periodic intervals for a week. These collected samples were ana-
lyzed using appropriate ELISA kits. From the ELISA pilot studies, it was determined that the
concentration of E2 eluting from the scaffolds was above the maximum detection level and all
measurements were near saturation. A ten-fold dilution of the E2 samples and ELISA was per-
formed. E3 samples had absorbance values within the ELISA detection range and were not
diluted. The SpectraMax M2e multimode microplate reader was used to read the 96 well plates
absorbance values. From the absorbance values of standards, the four parameter logistic (4PL)
nonlinear regression model was drawn, and concentrations of unknown samples were back
calculated. For all the assays, the absorbance values at 405 nm were measured and recorded.
Hormonal activity. The hormonal activity of E2 in the 3D printed scaffolds was assessed
as follows. Plain PCL pellets, saline and different concentrations of E2 were used as controls.
Extruded filaments and 3D printed discs were used as unknowns. Before these scaffolds were
seeded, 90% confluent endometrial cells were detached from the culture tubes and suspended
in RPMI medium. Each well was filled with 10 μl of suspension and incubated for 24 hours for
3D printing of estrogen and progesterone hormones
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attachment. Scaffolds were added to these wells and incubated for another 16 hours. Lysis
buffer was added to each well and incubated for two minutes. In a new 96 well plate, 20 μl of
this lysate was transferred, and 100 μl of luciferase substrate is added. Optical density of each
well was immediately read using a luminometer.
Statistical analysis
For the ELISA assay, three samples of each batch were tested and averaged for reproducibility.
Standard deviations of the means were calculated and mentioned in the elution profile graphs
as error bars. For the in-vitro study, measurements from five wells of each group were aver-
aged. A one-way ANOVA was conducted to analyze the significant difference between the
means among the groups. The standard deviation of the means was calculated and represented
as error bars in the graphs.
Results
PCL pellets were successfully coated with E1, E2, E3 and progesterone hormones. Each 20 gm
batch of 1.75 mm diameter filaments were extruded, and the required constructs were success-
fully printed. Fig 2 shows images of PCL constructs printed with and without hormones using
Fig 2. 3D printed constructs A) Control donut shaped pessary, B) Control Gellhorn shaped pessary, C) Control IUD, D) Pessary printed combinations of
filaments (red- PLA and white- PCL-E2), E) PCL-E1 IUD, and F) PCL-E2 IUD.
https://doi.org/10.1371/journal.pone.0182929.g002
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the Makerbot 3D printer. Constructs containing a combination of hormones can be printed
using this technique. Fig 2D shows a donut shaped pessary printed with unloaded polylactic
acid (PLA) filament (red) and with PCL filament (white) loaded with E2 hormone. Fig 3
shows of surgical mesh printed using PCL-Estrogen and an IUD, rod shaped implant 3D
printed using Progesterone loaded PCL filaments.
Scanning electron microscopy (SEM)
SEM was used to study the surface morphology of the coated pellets, filaments, and printed
discs. Fig 4 shows the SEM images of estrogen hormones E1, E2, and E3.
All these hormones contain irregularly shaped particles of varied sizes. The estimated larg-
est size of these particles was around 5 μm. Filaments extruded from ExtrusionBot were
Fig 3. 3D printed PCL-Estrogen mesh, PCL-Progesterone IUD, and Subdermal implant.
https://doi.org/10.1371/journal.pone.0182929.g003
Fig 4. SEM images of hormones. A) E1, B) E2, C) E3.
https://doi.org/10.1371/journal.pone.0182929.g004
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cylindrical in shape and had a smooth external surface. The SEM image in Fig 5 shows hor-
mone loaded PCL filaments extruded using the ExtrusionBot filament extruder.
Extruded filaments were used in Makerbot 3D printer to print discs of 5 mm × 1 mm
dimensions. Figs 6, 7A and 7B shows all 3D printed discs used for ELISA and cell culture at
25X magnification. These images exhibit layers of filaments comprising cylindrical shape with
300 μm in diameter and the sintering between the layers. On further magnification, hormone
particles were seen on the surfaces of these discs. Figs 6, 7C and 7D shows E1, E2, E3 and Pro-
gesterone particles on the surfaces of the discs.
Fig 5. SEM images of filaments. A) E1, B) E2, C) E3.
https://doi.org/10.1371/journal.pone.0182929.g005
Fig 6. SEM images of discs. (A, C) PCL-E1 Discs, (B, D) PCL-E2 Discs.
https://doi.org/10.1371/journal.pone.0182929.g006
3D printing of estrogen and progesterone hormones
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Thermal properties
All the hormones started thermal degradation at 190–240˚C and PCL degradation was
observed to start at 280˚C (Fig 8). The estradiol thermogram shows a 4% reduction in weight
at 100˚C suggesting the presence of residual moisture in the estradiol sample.
While the hormones initially had degradation temperatures ranging from 190–240˚C,
incorporating them in PCL matrix rendered both hormones and PCL more thermally stable.
Thermal degradation of all the 3D printed composites containing PCL matrix and hormones
had degradation starting at 310˚C (Fig 9).
Differential scanning calorimetry results suggest the changes in Tg and Tm of the polymer
composites was not pronounced as shown in Fig 10. Small changes in Tg were observed in the
composites when compared with PCL. Glass transition temperature of PCL was observed to be
at -62.8˚C while the composites’ Tg ranged from -64.9˚C to -63.3˚C. For PCL, Tm was observed
to be 61.7˚C and the composites had melting temperatures ranging from 65.2˚C to 58.5˚C.
X-ray diffraction
Diffractograms of PCL and hormones show their amorphous and crystalline phases (Fig 11).
Crystalline phases in PCL are attributed to the strong peaks at 21.4˚ and 23.8˚. Amorphous
scatter of PCL is observed over a range of 14˚ to 25˚. Crystalline scatter of estriol is seen at
13.2˚ and 20.5˚. Multiple crystalline scatter peaks were observed for estradiol at 13.4˚, 15.9˚,
18.4˚, 20.6˚, 22.8˚, and 26.8˚. Peaks observed at 14.5˚, 15.2˚, 17.4˚, 18.4˚, and 20.2˚ for estrone
Fig 7. SEM images of discs. (A, C) PCL-E3 Discs, (B, D) PCL-Progesterone Discs.
https://doi.org/10.1371/journal.pone.0182929.g007
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are due to the crystalline phase in the powder. Crystalline scatter peaks for progesterone were
observed at 10.7˚, 12.8˚, and 17˚. For all the hormones, amorphous scatter was seen as a large
bump at 2θ ranging from 10˚ to 30˚. Diffractograms of PCL-hormone composites are shown
in Fig 12. All the diffractograms had the same pattern as PCL polymer.
LC-MS/MS detection of hormones from implants
Using LC-MS, successful detection, separation and absolute quantification of different hor-
mones (E1, E2, E3, and Progesterone) were performed, given the same transitions (271.3/
133.0) for E1 and E3 (S1 Fig). The elution of hormones from the column is based on the
hydrophilicity of analyte with E3 eluting first followed by E2 and E1. The results are further
confirmed by comparing these findings to their respective peaks in UV chromatogram at
260nm. The concentrations of different hormones in the constructs were also determined with
a control (negative) where no analytes were detected (S2 Fig).
Quantification through ELISA
Preliminary studies showed the release of hormones were in nanograms concentration. A ten-
fold dilution of the samples was done to meet the ELISA kits detection range. Samples were
collected, one for each day. For the first two days, 35% of total hormone was released from the
scaffolds.
Fig 13 shows the concentration of hormone E2 released over a period of one week. A total
of 215 ng/mL of the cumulative concentration of E2 hormone was released at the end of day
Fig 8. TGA thermograms of PCL and hormones.
https://doi.org/10.1371/journal.pone.0182929.g008
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seven. Even after seven days, small quantities of hormone release within the working concen-
tration (2 ng/mL -5 ng/mL) were measured.
All the hormone loaded discs were 3D printed at 300 μm resolution. Preliminary tests
showed the release of E3 hormones from the constructs were within the detectable range of the
ELISA kits. For the first two days, 46% of total E3 hormone was released from the scaffolds.
On day seven, 1.3 ng/mL hormone was released.
Fig 13 also shows the cumulative concentration of E3 released from PCL scaffolds for seven
days. A standard graph plotted from the known concentration was used to yield a four param-
eter logistic curve. E3 release increased during the first four days, after which hormonal elution
was steady and extended. A total of 118 ng/ml (cumulative concentration) of E3 hormone was
released by the end of day four.
In vitro assay
Fig 14 shows the Relative Light Unit (RLU) values of luciferase activity in response to estrogen
stimuli. Five wells of each group were tested and ANOVA was conducted. The difference
between the control cells and control PCL pellets was not statistically significant (p 0.05),
indicating that the PCL pellets are biocompatible and do not promote any estrogen induced
pathways. The group containing E2 showed a robust increase in RLU values when compared
to groups without inducing agent, indicating the presence of bioactive compounds in the fabri-
cated constructs. Wells containing 100 pg/ml concentration of E2 showed a total of 84.6%
more luciferase activity. Luciferase activity for extruded filaments (1 cm length) and 3D
printed discs (5 mm X 1mm) increased by 80.85% and 74.9%, respectively, when compared to
the control cells activity.
Fig 9. TGA thermograms of PCL-hormones composites.
https://doi.org/10.1371/journal.pone.0182929.g009
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Discussion
Fused deposition modeling was used to fabricate hormone loaded biodegradable implant materi-
als. PCL pellets were coated with estrogen (E1, E2, E3) and progesterone, then filaments of
required dimensions were successfully extruded. With these bioactive enhanced filaments, con-
structs of relevant designs were fabricated using 3D printing. SEM images showed extruded fila-
ments were smooth and cylindrical in nature. Thermal properties of the PCL, hormones and
composites indicate that 3D printing can be achieved well below their degradation temperatures.
Given that thermal degradation of both the hormones and PCL polymer began at 190˚C or
greater and 3D printing of all the constructs was done at 130˚C, it can be inferred that both hor-
mones and polymer were not thermally degraded during the 3D printing process. Additionally,
the transitional temperatures of the 3D printed constructs were not greatly affected due to the
presence of hormones. The absence of amorphous scatter (other than PCL) in the diffractograms
may signify that changes in crystalline phases of hormones did not occur. As the composites had
low concentration of 1% w/w, it is possible that the x-rays could not interact with hormones to
cause any diffraction or the heating during the 3D printing process may have affected their crys-
talline phases.
The chromatographic peaks for hormones E1, E2, E3, and progesterone show the presence
of bioactive compounds in 3D printed constructs. The study of release kinetics using ELISA
assay showed that the hormones E2 and E3 were released at a steady rate from the scaffolds
over a short period. In vitro assays conducted on estrogen receptor luciferase reporter cell lines
show that the fabricated scaffolds were biocompatible. Groups enhanced with hormones
showed robust luciferase activity, indicating the presence of a bioactive inducing substance
(E2) in the scaffolds.
Fig 10. DSC thermogram of PCL-hormone composites.
https://doi.org/10.1371/journal.pone.0182929.g010
3D printing of estrogen and progesterone hormones
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Bioactive 3D printing has been the focus of several in vitro investigations to deliver antibiot-
ics and chemotherapeutics. Weisman et al. [12] used fused depositional modeling to create
3D-printed gentamicin- and methotrexate-laden constructs. The drug-laden bioactive con-
structs showed antimicrobial and tumor-inhibiting effects, both with favorable elution profiles.
In another study, this concept was implemented in antibiotic and chemotherapeutic impreg-
nated catheters and showed similar in vitro results [13]. Ballard et al. [14] used fused deposi-
tion modeling to create customized surgical meshes. In that study, gentamicin-laden meshes
inhibited bacterial growth compared to none by control 3D-printed surgical meshes.
There have been few studies that use 3D printing for implications in obstetrics and gynecol-
ogy. Tudela et al. [15] used prenatal ultrasound measurements of cervical length and radius to
fabricate custom 3D printed cerclage pessaries. Hakim et al. [16] fabricated vaginal stents and
dilators of customizable sizes and shapes from computed tomographic-acquired data from
commercial products. In radiation oncology, 3D printing has been used in a small number of
patients to fabricate custom vaginal cylinders for vaginal brachytherapy [17–19]. Sethi et al.
[19] reported 3D printing custom vaginal applicators for brachytherapy in patients with
Fig 11. XRD diffractograms of polymer and hormones.
https://doi.org/10.1371/journal.pone.0182929.g011
3D printing of estrogen and progesterone hormones
PLOS ONE | https://doi.org/10.1371/journal.pone.0182929 August 10, 2017 13 / 17
unique and postsurgical vaginal anatomy. Finally, the creation of bioprosthetic ovaries in mice
has been facilitated using 3D printing. Laronda et al. [20] 3D printed porous gelatin scaffolds
with stiffness to mimic ovarian tissue (based on reference standards) and pore size and mor-
phology to accommodate ovarian follicles. After substantiating their finding in vitro, they
implanted the 3D printed ovarian-like implants into mice with oophorectomies. These scaf-
folds were populated with ovarian follicles in various stages of maturity. Over time, the
Fig 12. XRD diffractograms of PCL-hormones composites.
https://doi.org/10.1371/journal.pone.0182929.g012
Fig 13. Cumulative concentration of E2 and E3 released from PCLcomposite discs (mean ± SD, n = 3).
https://doi.org/10.1371/journal.pone.0182929.g013
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development of these bioprosthetic ovaries demonstrated folliculogenesis and development of
blood vessels throughout the scaffolds. Further, three of seven mice with 3D printed biopros-
thetic ovaries demonstrated fertility and bore offspring [20].
The present study offers the first data to show hormone-laden 3D printed constructs. While
the potential benefits, pitfalls, and clinical correlates for the estrogen and/or progesterone-elut-
ing constructs fabricated in this study are unclear, the ability to impregnate 3D printed con-
structs with bioactive hormones portends new possibilities in additive manufacturing of
implants and devices.
The resolution of the 3D printed constructs can be changed by altering the layer height of
the deposited filament. With decrease in layer height of the filament, surface area of the con-
struct increases and should, in turn, increases the hormonal release.
The ability to 3D print estrogen and/or progesterone-loaded biodegradable implants holds
great potential in personalized medicine. Using these methods, IUDs, and pessaries could be
tailored to a patient’s specific needs in aspects of the unique anatomy of the individual, hor-
mone dosage and period of hormone therapy.
Supporting information
S1 Fig. LC-MS/MS chromatogram. LC-MS/MS chromatogram of the standard hormone
solutions showing the E1, E2, E3 and Progesterone peaks.
(TIF)
S2 Fig. Chromatographic LC/MS analysis. Chromatographic LC/MS analysis of the 3D
printed constructs with control, E1, E2, E3 and Progesterone hormones.
(TIF)
Fig 14. RLU values of Estrogen receptor luciferase reporter cells incubated with different groups of E2 scaffolds
(mean ± SD, n = 5).
https://doi.org/10.1371/journal.pone.0182929.g014
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